Apr. 1 at 4:02 PM
$PALI
Exec Summary
--Palisade Bio is a clinical-stage biopharmaceutical company focused on developing oral, targeted therapeutics for autoimmune, inflammatory, and fibrotic diseases.
--Core Focus: Ulcerative Colitis (UC) and Crohn’s Disease (CD). The company uses a precision medicine approach to identify patients most likely to respond to therapy.
--Following a major recapitalization in late 2025 (funded at
$0.70/share), the company is well-funded with
$133.4 million in cash, providing a runway through high-value clinical readouts in 2028.
Pipeline and Mechanism of Action
--Lead Candidate: PALI-2108: An oral, once-daily, colonic-activated PDE4 inhibitor prodrug.
--Targeted Delivery: Unlike systemic PDE4 inhibitors (which often cause nausea and diarrhea), PALI-2108 is engineered to remain inactive until it reaches the lower intestine, where bacterial enzymes (β-glucuronidase) convert it into the active drug. This gut-restricted approach aims to bypass the systemic side effects (nausea/vomiting) that have historically limited other PDE4 inhibitors.
--Dual Action: Demonstrated both anti-inflammatory and anti-fibrotic effects in preclinical models as well as shown to normalize 186 genes specifically linked to fibrosis and Crohn’s strictures, which is particularly relevant for Fibrostenotic Crohn’s Disease (FSCD).
--Precision Medicine: Utilizing a biomarker-based approach to select patients, aiming to improve clinical response rates compared to unselected populations.
Catalyst Readout Timeline
--Q2 2026: Anticipated Phase 2 UC Study Initiation (IND submission).
--H2 2026: Anticipated Phase 2 CD Study Initiation (IND submission).
--H2 2027: Expected Phase 2 UC Efficacy Readout.
--2028: Expected Phase 2 CD Efficacy Readout.
Competition and Competitive Positioning
--Established Biologics: Competes with TNF antibodies (Humira, Remicade), IL-23 inhibitors (Skyrizi, Tremfya), and JAK inhibitors (Rinvoq).
--The "Safety-Efficacy" Gap: Systemic small molecules like JAK inhibitors often carry black-box warnings; PALI-2108’s localized activation aims for biologic-level efficacy with a superior safety and tolerability profile.
--FSCD Niche: Currently, there are no FDA-approved pharmacologic treatments specifically for the fibrotic component of Crohn's, positioning PALI-2108 as a potential first-in-class therapy.
--Speed to Healing: Recent Phase 1b data in FSCD patients showed 40% endoscopic remission in just 14 days, significantly faster than the 12-week timeframe typical for leading biologics.
Capital Structure (As of December 31, 2025)
--Fully Diluted Share Count: Approximately 248,491,985 shares (includes outstanding common stock, ~52 million pre-funded warrants, and securities convertible into common stock).
--Fully Diluted Market Cap: Approximately
$497.0 million (calculated at the requested price of
$2.00/share).
--Cash Position:
$133.4 million as of Dec 2025. Runway through Phase 2 CD efficacy readout in 2028.
Team
--J. Finley: CEO, CFO, and Director. Former CFO of Adastra Pharmaceuticals
--Mitchell Jones, MD, PhD: President and Chief Medical Officer. Former leadership roles at Arena Pharmaceuticals and Pfizer, with a focus on clinical development and translational medicine.
--Sharon Skare: VP, Global Head of Clinical Operations. Former Clin Ops at Abivax led global Phase 2/3 IBD programs.
--Recent Clinical Advisory Board Updates (Q1 2026):
----Bram Verstockt, MD, PhD: A global leader in IBD precision medicine from KU Leuven, focused on molecular characterization of IBD.
----Laurent Peyrin-Biroulet, MD, PhD: Professor of Gastroenterology and former President of ECCO; a top global authority on IBD clinical trial design.
----David T. Rubin, MD: Chief of Gastroenterology, Hepatology, and Nutrition at the University of Chicago and a leading expert in clinical IBD management.
Bull Thesis
--Validation of Localized Delivery: If Phase 2 trials confirm that PALI-2108 avoids the typical PDE4-related toxicity (nausea/vomiting), it becomes a highly attractive oral alternative to injectable biologics.
--Confirmation of Niche: 41% mean increase in ileal cAMP (target engagement) proves the drug reaches the terminal ileum effectively—the hardest part of the gut to target orally.
--Fast-Acting Profile: Achieving 47.5% SES-CD reduction in only 2 weeks suggests a potentially superior speed of healing compared to
$10B+ blockbusters.
--Precision Medicine Advantage: Success in identifying "high-responders" via biomarkers could result in "best-in-class" efficacy data, making it a prime candidate for acquisition by large pharma.
--Addressing Unmet Needs: FSCD represents a massive, underserved market where PALI-2108 faces minimal direct competition.
--Strategic Expansion: The pivot to include broader luminal CD more than doubles the addressable market and creates a clearer regulatory path for approval.
Bear Thesis
--Clinical Execution Risk: While Phase 1b UC and FSCD data was positive (100% (UC) and 40% (FSCD) clinical response in 5 patients), the sample size is extremely small and may not be reproducible in larger, placebo-controlled Phase 2 trials.
--Regulatory Hurdles: The FDA may not accept data from the Canadian Phase 1 trials to support U.S. registration, potentially causing delays or requiring redundant studies.
--Competitive Crowd: The IBD space is highly crowded with new oral entrants (S1P1s and TYK2s) that may limit the commercial market share even if PALI-2108 is approved.
